JP2022501429A5 - - Google Patents
Info
- Publication number
- JP2022501429A5 JP2022501429A5 JP2021539486A JP2021539486A JP2022501429A5 JP 2022501429 A5 JP2022501429 A5 JP 2022501429A5 JP 2021539486 A JP2021539486 A JP 2021539486A JP 2021539486 A JP2021539486 A JP 2021539486A JP 2022501429 A5 JP2022501429 A5 JP 2022501429A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- cycloalkyl
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024227127A JP2025066704A (ja) | 2018-09-18 | 2024-12-24 | 特定の白血病を治療するための化合物 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862733029P | 2018-09-18 | 2018-09-18 | |
| US62/733,029 | 2018-09-18 | ||
| US201962816637P | 2019-03-11 | 2019-03-11 | |
| US62/816,637 | 2019-03-11 | ||
| US201962889929P | 2019-08-21 | 2019-08-21 | |
| US62/889,929 | 2019-08-21 | ||
| PCT/US2019/051567 WO2020061086A2 (en) | 2018-09-18 | 2019-09-17 | Compounds for treating certain leukemias |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024227127A Division JP2025066704A (ja) | 2018-09-18 | 2024-12-24 | 特定の白血病を治療するための化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022501429A JP2022501429A (ja) | 2022-01-06 |
| JP2022501429A5 true JP2022501429A5 (enExample) | 2022-09-27 |
| JP7611832B2 JP7611832B2 (ja) | 2025-01-10 |
Family
ID=69774840
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021539486A Active JP7611832B2 (ja) | 2018-09-18 | 2019-09-17 | 特定の白血病を治療するための化合物 |
| JP2024227127A Pending JP2025066704A (ja) | 2018-09-18 | 2024-12-24 | 特定の白血病を治療するための化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024227127A Pending JP2025066704A (ja) | 2018-09-18 | 2024-12-24 | 特定の白血病を治療するための化合物 |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US10889571B2 (enExample) |
| EP (1) | EP3852745A4 (enExample) |
| JP (2) | JP7611832B2 (enExample) |
| KR (2) | KR20210061377A (enExample) |
| CN (3) | CN112770745B (enExample) |
| AU (2) | AU2019342102C1 (enExample) |
| BR (1) | BR112021004051A2 (enExample) |
| CA (1) | CA3110576A1 (enExample) |
| CL (1) | CL2021000637A1 (enExample) |
| CO (1) | CO2021004704A2 (enExample) |
| IL (2) | IL281427B2 (enExample) |
| MA (1) | MA53664A (enExample) |
| MX (2) | MX2021003093A (enExample) |
| NZ (1) | NZ773110A (enExample) |
| PE (2) | PE20252740A1 (enExample) |
| SG (1) | SG11202102367TA (enExample) |
| TW (1) | TWI826525B (enExample) |
| WO (1) | WO2020061086A2 (enExample) |
| ZA (1) | ZA202101304B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ773110A (en) | 2018-09-18 | 2024-11-29 | Terns Inc | Compounds for treating certain leukemias |
| MX2021003904A (es) | 2018-10-05 | 2021-10-26 | Annapurna Bio Inc | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor apj. |
| CN111320609A (zh) | 2018-12-13 | 2020-06-23 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
| IL312955B1 (en) | 2019-03-11 | 2026-01-01 | Inflarx Gmbh | Fused piperidinyl bicyclic compounds and related compounds as C5a receptor modulators |
| WO2021018194A1 (en) * | 2019-07-29 | 2021-02-04 | Ascentage Pharma (Suzhou) Co., Ltd. | Heterocyclic compounds as bcr-abl inhibitors |
| AU2020336272A1 (en) | 2019-08-23 | 2022-04-14 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| WO2021050945A1 (en) | 2019-09-12 | 2021-03-18 | Terns, Inc. | Thyroid hormone receptor beta agonist compounds |
| PE20240097A1 (es) * | 2021-03-03 | 2024-01-18 | Terns Pharmaceuticals Inc | Compuestos agonistas beta del receptor de la hormona tiroidea |
| CN116375650B (zh) * | 2022-12-30 | 2025-08-05 | 浙江美诺华药物化学有限公司 | 一种替戈拉生中间体的制备方法 |
| EP4568664B1 (en) | 2023-04-07 | 2026-04-01 | Terns Pharmaceuticals, Inc. | Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating obesity |
| TW202525293A (zh) | 2023-08-31 | 2025-07-01 | 美商拓臻製藥公司 | 用於治療癌症之組合 |
| WO2025226724A1 (en) | 2024-04-23 | 2025-10-30 | Terns Pharmaceuticals, Inc. | Bcr-abl1 inhibitors for use in treating cancer |
| CN120842151A (zh) * | 2024-04-26 | 2025-10-28 | 北京英飞智药科技有限公司 | 一种2-芳基苯并咪唑类化合物及其制备方法与应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9910642A (pt) * | 1998-05-22 | 2001-10-09 | Avanir Pharmaceuticals | Análogos de benzimidazol como reguladores descendentes de ige |
| SE0003476D0 (sv) | 2000-09-28 | 2000-09-28 | Astrazeneca Ab | Compounds |
| TW200304820A (en) * | 2002-03-25 | 2003-10-16 | Avanir Pharmaceuticals | Use of benzimidazole analogs in the treatment of cell proliferation |
| TW200716110A (en) * | 2005-04-20 | 2007-05-01 | Smithkline Beecham Corp | Inhibitors of AKT activity |
| CN101553468A (zh) * | 2006-10-18 | 2009-10-07 | 诺瓦提斯公司 | 有机化合物 |
| AR063311A1 (es) * | 2006-10-18 | 2009-01-21 | Novartis Ag | Compuestos organicos |
| GB0800035D0 (en) | 2008-01-02 | 2008-02-13 | Glaxo Group Ltd | Compounds |
| WO2013033093A1 (en) | 2011-08-29 | 2013-03-07 | Biocryst Pharmaceuticals, Inc. | Heterocyclic compounds as janus kinase inhibitors |
| PE20161416A1 (es) | 2012-05-15 | 2017-01-08 | Novartis Ag | Derivados de benzamida para la inhibicion de la actividad abl1, abl2 y bcr-abl1 |
| WO2013171642A1 (en) | 2012-05-15 | 2013-11-21 | Novartis Ag | Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 |
| CA2870339C (en) | 2012-05-15 | 2020-06-02 | Novartis Ag | Compounds and compositions for inhibiting the activity of abl1, abl2 and bcr-abl1 |
| BR112014030940B1 (pt) | 2012-06-11 | 2022-09-06 | UCB Biopharma SRL | Benzimidazóis que modulam tnf-alfa e composição farmacêutica compreendendo os mesmos |
| CN103113355B (zh) | 2013-02-27 | 2014-08-13 | 无锡爱内特生物科技有限公司 | 一种Bcr/Abl酪氨酸激酶抑制剂及其制备方法和在治疗慢性粒细胞白血病中的应用 |
| GB201401086D0 (en) | 2014-01-23 | 2014-03-12 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| US9931342B2 (en) | 2016-02-02 | 2018-04-03 | Duke University | Compositions and methods for the treatment of cancer |
| CN109790144A (zh) | 2016-04-29 | 2019-05-21 | 爱仕达生物技术有限责任公司 | 新型杂环化合物作为酪氨酸激酶bcr-abl抑制剂 |
| ES2864405T3 (es) | 2017-01-20 | 2021-10-13 | Shenzhen Targetrx Inc | Compuesto de (hetero)arilamida para inhibir la actividad de proteína quinasa |
| EP3553057B1 (en) | 2017-01-20 | 2022-10-26 | Shenzhen TargetRx, Inc. | (hetero)arylamide compound for inhibiting protein kinase activity |
| WO2018191146A1 (en) * | 2017-04-10 | 2018-10-18 | Navitor Pharmaceuticals, Inc. | Heteroaryl rheb inhibitors and uses thereof |
| US11649218B2 (en) | 2018-03-09 | 2023-05-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | C-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same |
| NZ773110A (en) | 2018-09-18 | 2024-11-29 | Terns Inc | Compounds for treating certain leukemias |
| US20240262842A1 (en) | 2021-04-27 | 2024-08-08 | Merck Sharp & Dohme Llc | Small molecule inhibitors of kras g12c mutant |
| EP4410779A4 (en) | 2021-09-30 | 2025-07-30 | Jiangsu Hansoh Pharmaceutical Group Co Ltd | FOUR-MEMBERED FUSED RING COMPOUND, PREPARATION METHOD AND USE THEREOF |
| TW202502333A (zh) | 2023-03-30 | 2025-01-16 | 大陸商江蘇豪森藥業集團有限公司 | 四元稠環類化合物鹽晶型及其製備方法和應用 |
| TW202525293A (zh) | 2023-08-31 | 2025-07-01 | 美商拓臻製藥公司 | 用於治療癌症之組合 |
-
2019
- 2019-09-17 NZ NZ773110A patent/NZ773110A/en unknown
- 2019-09-17 CA CA3110576A patent/CA3110576A1/en active Pending
- 2019-09-17 CN CN201980060896.3A patent/CN112770745B/zh active Active
- 2019-09-17 MA MA053664A patent/MA53664A/fr unknown
- 2019-09-17 KR KR1020217011001A patent/KR20210061377A/ko active Pending
- 2019-09-17 JP JP2021539486A patent/JP7611832B2/ja active Active
- 2019-09-17 BR BR112021004051-0A patent/BR112021004051A2/pt unknown
- 2019-09-17 KR KR1020267002852A patent/KR20260019669A/ko active Pending
- 2019-09-17 WO PCT/US2019/051567 patent/WO2020061086A2/en not_active Ceased
- 2019-09-17 SG SG11202102367TA patent/SG11202102367TA/en unknown
- 2019-09-17 PE PE2025001942A patent/PE20252740A1/es unknown
- 2019-09-17 PE PE2021000343A patent/PE20211644A1/es unknown
- 2019-09-17 AU AU2019342102A patent/AU2019342102C1/en active Active
- 2019-09-17 IL IL281427A patent/IL281427B2/en unknown
- 2019-09-17 CN CN202210969394.6A patent/CN115448908B/zh active Active
- 2019-09-17 EP EP19862388.6A patent/EP3852745A4/en active Pending
- 2019-09-17 CN CN202210968772.9A patent/CN115215838B/zh active Active
- 2019-09-17 MX MX2021003093A patent/MX2021003093A/es unknown
- 2019-09-17 IL IL322515A patent/IL322515A/en unknown
- 2019-09-17 US US16/573,860 patent/US10889571B2/en active Active
- 2019-09-17 TW TW108133432A patent/TWI826525B/zh active
-
2021
- 2021-02-25 ZA ZA2021/01304A patent/ZA202101304B/en unknown
- 2021-03-16 MX MX2023007714A patent/MX2023007714A/es unknown
- 2021-03-16 CL CL2021000637A patent/CL2021000637A1/es unknown
- 2021-04-15 CO CONC2021/0004704A patent/CO2021004704A2/es unknown
-
2023
- 2023-06-22 US US18/339,516 patent/US12240835B2/en active Active
-
2024
- 2024-12-20 AU AU2024287115A patent/AU2024287115A1/en active Pending
- 2024-12-24 JP JP2024227127A patent/JP2025066704A/ja active Pending
-
2025
- 2025-01-30 US US19/041,557 patent/US20250276961A1/en active Pending
- 2025-03-06 US US19/072,824 patent/US12454524B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022501429A5 (enExample) | ||
| US10501456B2 (en) | Therapeutic agents for the treatment of HBV infection | |
| US20080182845A1 (en) | Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection | |
| JP2023022227A (ja) | 肝線維症を治療する方法 | |
| RU2018131766A (ru) | 6-гетероциклил-4-морфолин-4-илпиридин-2-оны, пригодные для лечения рака и диабета | |
| JP2019505595A5 (enExample) | ||
| JP5667684B2 (ja) | 関節炎の治療方法 | |
| RU2013108641A (ru) | Способ лечения офтальмологических заболеваний с использованием соединений ингибиторов киназы в пролекарственных формах | |
| JP2020500866A5 (enExample) | ||
| JP2015531773A (ja) | スルファモイル−アリールアミド及びｂ型肝炎の治療のための薬剤としてのその使用 | |
| JP2011509309A5 (enExample) | ||
| JP2015524472A5 (enExample) | ||
| US20160175316A1 (en) | Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection | |
| CA3178372A1 (en) | Enpp1 modulators and uses thereof | |
| JP2023530316A5 (enExample) | ||
| RU2018131775A (ru) | 6-арил-4-морфолин-1-илпиридоны, пригодные для лечения рака или диабета | |
| JP2019505594A5 (enExample) | ||
| RU2012130929A (ru) | Гетероциклические соединения в качестве ингибиторов янус-киназы | |
| RU2012147511A (ru) | Применение ингибиторов c-src в комбинации с пиримидиламинобензамидом для лечения лейкоза | |
| RU2018106504A (ru) | Производные пиридин 3-ил-уксусной кислоты в качестве ингибиторов репликации вируса иммунодефицита человека | |
| EP3286179A1 (en) | Compositions and methods for inhibiting kinases | |
| JP2023544716A5 (enExample) | ||
| JP4774995B2 (ja) | アシルアミノチアゾール誘導体を有効成分とする医薬組成物 | |
| JP2021531308A5 (enExample) | ||
| RU2019114205A (ru) | Способы лечения глазного заболевания с применением ингибиторов csf-1r |